Methods: Tumor-infiltrating leukocytes were phenotyped in biopsies from 459 patients with cHL. Time to progression (TTP) (primary progression, relapse, or death from cHL) and overall survival were analyzed using Cox proportional hazards regression.
| INTRODUCTION
Despite the excellent overall survival (OS) in classical Hodgkin lymphoma (cHL), some patients suffer progression or relapse. 1 response. 2 Galon et al 3 studied total T lymphocytes (CD3), cytotoxic T lymphocytes (CD8), and memory T lymphocytes (CD45RO) on tumor tissue sections with immunohistochemical markers in colorectal carcinoma. High numbers of each marker in the center of the tumor and in the invasive margin were independently associated with superior outcome and were superior predictors of outcome compared to the TNM-classification. 3 However, hematological malignancies such as cHL differ from solid carcinomas in several aspects. First, the cHL microenvironment does not contain central parts and invasive margins.
Second, the malignant HRS cells are scarce compared to the surrounding infiltrate of leukocytes. 2 A certain immune signature might be predictive of response to conventional therapy but may also provide guidance to possible responders of immune checkpoint inhibitors. The prognostic significance of different tumor-infiltrating leukocytes in cHL has been studied extensively but is still unclear due to ambiguous results, 2 and no previous study has tried to determine a distinct immune signature associated with inferior outcome. 3 In a recent publication from our research group on a pediatric population with cHL, 4 high numbers of mast cells and macrophages correlated with advanced stage and laboratory parameters associated with dismal outcome.
In this study, our aim was to investigate if a certain immune signature correlates with outcome by studying a limited number of leukocytes, analogous to the approach by Galon et al 3 but adjusted to the cHL microenvironment. Based on previous studies, a high number of activated lymphocytes (including cytotoxic T lymphocytes (CTL) and natural killer (NK) cells) 5 was defined as an active immune signature, a high number of regulatory T lymphocytes (Tregs) as an anergic immune signature, 6 and a high number of eosinophils, 7 mast cells, 8 and macrophages, 9,10 respectively, as an innate immune signature. As activated lymphocytes are able to kill tumor cells, Tregs maintain an immune suppressive state in tumors, 11 and eosinophils, mast cells, and macrophages support tumor cell growth by maintaining chronic inflammation, our a priori hypothesis was that prognosis should be poorer for patients with an anergic or innate immune signature compared with patients with an active immune signature. We studied these leukocytes in tumor sections from 459 cHL patients and correlated the findings with clinical characteristics, including OS and time to progression (TTP).
| MATERIALS AND METHODS

| Patients
In the Scandinavian Lymphoma Etiology (SCALE) study, a populationbased case-control study of Swedish and Danish patients aged 18-74 years diagnosed between January 1999 and August 2002,  12 585 patients with cHL (nodular sclerosis, mixed cellularity (MC), lymphocyte rich, lymphocyte depleted, and not otherwise specified) were included 13 ( Figure 1 ). All patients were also interviewed for potential risk factors for cHL, and clinical data were gathered. 
| Immunohistochemical staining
Slides were prepared using 3-4 μm thick sections cut from paraffin- 
| Evaluation of tumor-infiltrating leukocytes
Eosinophils were evaluated on slides stained with hematoxylin-eosin. Tregs and activated lymphocytes were counted in 3 to 5 randomly selected HPF at 400x magnification. The total number of inflammatory cells within a field was counted, with the percentage of Tregs and activated lymphocytes then calculated. All inflammatory cells were evaluated using a microscope equipped with a lattice square net in fields with HRS cells, while fibrotic and necrotic areas were avoided.
| Categorization of leukocytes
The number and proportion of tumor-infiltrating leukocytes were 
| Categorization of immune signatures
An active immune signature was defined as a high proportion of acti- 
| Statistical methods
Associations between the leukocytes in the tumor microenvironment in relation to each other and to age, histology, sex, EBV-status, Death from cHL was defined as death with active lymphoma disease (after primary progressive disease and/or relapses occurred). OS was defined as survival from initial diagnosis to death from any cause.
To be a participant in the SCALE study, the patient had to answer a questionnaire at an interview. To counter the potential survivor bias inherent in this left truncation, start of follow-up was delayed until the latest of date of diagnosis and date of interview. That is, follow-up started at entry into the SCALE study, with time of diagnosis as the origin of the underlying time scale for Cox regression. Analyses were supplemented by stratification by age above and below 60 years, and by stage. Based on earlier experience, we find it likely that putative effects may be present only in some strata, while being completely absent in other strata and we have therefore taken a stratified approach recognizing the heterogeneity of cHL, despite relatively low statistical power and multiple testing. The statistical analyses were performed using SAS version 9.4. Statistical tests were two-sided, and P-values < .05 were considered statistically significant. Confidence intervals (CI) for hazard ratios (HR) were based on Wald tests.
| Ethics
The study was approved by the Danish Data Protection Agency and by ethics committees according to the Declaration of Helsinki in both countries. Informed consent was obtained from all participants.
| RESULTS
| Macrophages correlate with several wellknown indicators of inferior prognosis
In (Table S1 ). Among clinicopathological parameters, a high level of macrophages correlated with EBV-positivity and MC, and with well-known negative prognostic factors such as advanced stage, high ESR, low Hb, low WBC, bulky tumor, and bone marrow involvement (Table S2) . Despite this, macrophages were not associated with TTP or OS ( Table 2 and Table S3 ). The number of mast cells correlated with an elevated ESR (Table S2) . A high proportion of Tregs correlated with younger age and high WBC while a high proportion of activated lymphocytes correlated with EBV-positivity, MC, older age, male sex, and low WBC (Table S2 ). 
| An active or an anergic immune signature is equally common
| A high proportion of Tregs (anergic immune signature) is associated with inferior outcome
Median follow-up time was 12.9 years. Sixty-two (15%) of 409 patients experienced an event (progression, relapse, or cHL death). associated with a superior OS in patients <60 years of age (Table S3) , and a high proportion of activated lymphocytes was associated with a shorter OS in limited stages (Table S3) .
| DISCUSSION
CHL shows a complex interplay between the immune cell-derived HRS cell and its microenvironment. It often presents with a highly variable inflammatory infiltrate with an absence of a central part and invasive margin which is commonly seen in other tumors as described in Galons et als "immunoscore" for colorectal carcinoma. 3 Hence, for tumors like cHL, there is a need for another type of immune classification for correlations to prognosis and possible prediction of patients that may benefit from immunotherapeutics such as immune checkpoint blockade antibodies.
We attempted herein to define suitable immune signatures for cHL in a large cohort of cHL patients treated according to national guidelines during a short and well defined time period. We divided the material into 
| Possible mechanisms
Tregs are able to suppress various inflammatory cells, not only the antitumor functions of CTL, but also NK cells, B lymphocytes, dendritic cells, and macrophages. 6 Thus, from a biological perspective, a high proportion of Tregs could theoretically lead to a reduced ability of the immune system to attack the tumor cells and a higher risk of progression, relapse and death from cHL, in line with our results and our a priori hypothesis. Patients with an anergic immune signature may have more aggressive tumor biology, causing the anergic state in the tumors, and/or a reduced ability to react with a proper immune response.
11
Immune checkpoint inhibitors, such as programed death receptor 1 (PD-1) inhibitors, were recently introduced as novel therapy in relapsed and refractory cHL, supposedly acting through re-activation of anergic CTL. 21, 22 PD-1 is also expressed by Tregs and promotes their function and proliferation. 23 It is thus possible that the effect of PD-1 inhibition is largely mediated through blockade of Tregs. 24 Tregs in the microenvironment in cHL might thus be a predictor of response to PD-1 blockade, and patients with a high expression of Tregs might be a subgroup of patients with a particular high risk of early progression and relapse in need of novel treatments already as first line.
| Comparison with previous studies regarding Tregs
In line with our investigation, only 1 previous study reports that a high number of Tregs was associated with an inferior outcome among 87
patients, but only in crude analysis. 25 In several other previous studies including between 63 and 257 patients, high numbers/proportions of Tregs have been associated with a favorable prognosis 20, [26] [27] [28] [29] [30] [31] (summarized in Table S4 ), which makes our contrasting results of particular interest to report. In most prior studies, cases were gathered over several decades, and different treatment regimens were used. 27, 31 Most of the studies included patients <18 years of age, which also might influence treatment given. In elderly patients, other factors than tumor biology may affect the prognosis (such as comorbidities), making the (Table S4) . A recent study that used flow cytometry in cHL patients treated with ABVD, found that high numbers of CD8 + and CD4 + lymphocytes were associated with better and poorer outcomes, respectively. 32 Although it is unclear how much of the CD4 + population was composed of Tregs, these findings are partly in line with ours. Based on our large cohort and the biological rationale of our findings, we believe it is too early to be definitive in considering a high proportion of Tregs as favorable for prognosis, despite the findings of earlier studies.
| Comparison with previous studies regarding eosinophils, mast cells, macrophages, and activated lymphocytes
Regarding the other cell types, no major implications on prognosis were observed. In patients with many eosinophils, we noted a trend (P = .06) for better OS overall, and, in young patients (<60 years) a statistically significantly better OS. Eosinophil cationic protein secreted by the eosinophils is cytotoxic to the HRS cells. 33 In studies where older treatments were used, a high number of eosinophils was associated with an adverse prognosis in 2 studies, 16, 34 but not in 2 other studies. 35, 36 The lack of prognostic implication of high mast cell infiltration in our data, in contrast to all 5,37-39 but 1 35 previous study, Hence, macrophages could be further subclassed to give insight into their role in the microenvironment. Several studies have found high numbers of macrophages measured both by CD68 and CD163 to be associated with an adverse prognosis, 18, 31, 38, [40] [41] [42] [43] [44] while other studies, in line with our results, showed no prognostic impact hereof. 19, 45, 46 For patients with a high number of activated lymphocytes, we noted a trend (P = .051) for shorter OS in univariate analyses compared to patients with a low number of activated lymphocytes, similar to most, 5, 20, 26, 29, 38 but not all 25, 36, 47 previous studies. However, in our age-adjusted analyses, the high presence of activated lymphocytes had no impact on outcome. We found that a high amount of activated lymphocytes correlated with several factors indicating an adverse prognosis, including older age, male sex, and EBV-positivity (Table S2 ). In summary, none of the inflammatory cell types predicated OS in the whole cohort, likely due to effective therapeutic rescue strategies for relapsing patients and the excellent prognosis in the cohort. Previous investigations could have been highly influenced by the variation in the number of activated lymphocytes and these well-known negative prognostic factors, particularly older age.
| Methods
Immunohistochemical antibodies are not always entirely specific for only 1 cell type. FoxP3 is used in all studies as a marker for 44 ; however, CD68 has been used in all earlier studies in cHL. 18, 19, 31, 38, [40] [41] [42] [43] [44] [45] [46] CD163 is considered to be a more specific marker for tumor-promoting macrophages (M2 macrophages). 9, 44 To identify activated lymphocytes such as CTLs, we used granzyme B, as in most previous studies. 20, 25, 26, 36, 41, 47 Granzyme B is expressed by activated CTLs after antigen recognition, by NK cells 49 but also to some extent by active Tregs. 50 However, the proportion of Tregs did not correlate with the proportion of activated lymphocytes (Table S1 ). This indicates a low misclassification risk between active Tregs and activated lymphocytes.
| Strengths and weaknesses
Strengths of our study include the predefined hypothesis, the population-based setting with histopathologic review of more than 90% of the cases, the homogenously treated large cohort, and the wide array of inflammatory cell markers evaluated with immunohistochemistry. We also had satisfactory intra-and interindividual reproducibility with our manual evaluation (supplemental text). Limitations include the lack of complete information on treatment received for the Danish patients; however, HRs for the association between a high amount of Tregs and TTP among Swedish patients were similar for those treated with ABVD or BEACOPP. Despite being the largest cohort to date, limitations of our results include low precision of effect estimates due to few outcomes. In addition, multiple testing could have generated some statistically significant estimates by chance, but all cut-offs were decided a priori.
| CONCLUSIONS
In summary, cHL can be divided into active, anergic, innate, or mixed immune signatures upon diagnosis. We believe that heterogeneous populations, gathered over several decades and using different outcomes in earlier studies could explain most of the differences in prognostic implications of tumor-infiltrating leukocytes between these studies and our study. In our study, a high amount of Tregs (anergic) indicated a shorter TTP, which we believe could be caused by ineffective immune-clearance of the malignant HRS cells and resistance to contemporary treatment regimens.
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